Vascular Access Devices – Market Insights – Asia Pacific

Over the forecast period, the Asia Pacific vascular access device market will grow moderately through 2030, driven by an expanding patient population and increasing adoption of premium-priced devices. Importantly, vascular access devices represent a key component of care for COVID-19 patients, and therefore the pandemic’s impact on procedure volumes, unit sales, and revenues has been incorporated into market projections.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for vascular access devices in the Asia Pacific countries across an 11-year period.

The COVID-19 global pandemic has had a dual effect on the vascular access market in the short term.

How have trends in vascular access device segments changed due to COVID-19?

What factors contribute to these market changes?

What plans are being executed by manufacturers in response to the pandemic?

How soon will procedure volumes, sales, and revenues recover to pre-pandemic levels?

Despite increasing failure rates and complications requiring reinsertion, short PIVC insertions continue to be one of the most common invasive procedures in the region.

What are the current clinical recommendations to reduce PIVC failure?

What are some of the measures taken by companies to improve PIVC insertion outcomes?

How will initiatives to educate nurses on PIVC insertion impact the unit sales of short PIVC?

Many competitors’ products are entering the vascular access device market in Asia Pacific.

How will new products launches impact the vascular access device market?

What challenges will new companies encounter in this space? Will they capture significant share from existing competitors?

Increasing incidence of CLABSI with CVC is resulting in a shift toward PICCs.

How is the rising adoption of PICCs impacting the sales of CVC units? How does this vary across the Asia Pacific countries?

What are the marketing strategies adopted by companies to promote PICC sales?

What are some of the clinical practices initiated to reduce CLABSI with CVCs? How will this impact the CVC market?

How will the markets for tunneled CVCs and antimicrobial devices perform through 2030?

Home care therapy continues to grow in most Asia Pacific countries.

What are some of the vascular access device markets likely to be impacted by the increasing adoption of home care therapy?